1. Value in Health Regional Issues
Long-Term Clinical Benefits of Canagliflozin 100 mg versus Sulfonylurea in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin in India 
Vishal Gupta, MD, Michael Willis, PhD, Pierre Johansen, MSc, Andreas Nilsson, MSc, Manan Shah, MBBS, MHA, Amey Mane, MD, Cheryl Neslusan, PhD 
Value in Health Regional Issues 
Volume 18, Pages (May 2019)
DOI: /j.vhri
Copyright © 2018 ISPOR--The professional society for health economics and outcomes research Terms and Conditions

2. Fig. 1
Percentage of patients taking insulin over 20 y in the base case.
Value in Health Regional Issues  , 65-73DOI: ( /j.vhri )
Copyright © 2018 ISPOR--The professional society for health economics and outcomes research Terms and Conditions

3. Fig. 2
Base-case and sensitivity analysis results for (A) health outcomes and (B) RRRs in selected microvascular complications, and (C) RRRs in selected macrovascular complications. Data are differences with canagliflozin 100 mg vs. glimepiride. CHF, congestive heart failure; CKD, chronic kidney disease; LY, life-year; MI, myocardial infarction; PDR, proliferative diabetic retinopathy; QALY, quality-adjusted life-year; RRR, relative risk reduction.
Value in Health Regional Issues  , 65-73DOI: ( /j.vhri )
Copyright © 2018 ISPOR--The professional society for health economics and outcomes research Terms and Conditions